Concentrations of free vascular endothelial growth factor in the maternal and foetal circulations during pregnancy: A cross-sectional study

Ali, K.Z.M.; Burton, Graham J.; Khalid, Mohammed E.; Moosa, Riyad A.; Abdalla, Salah E.

doi:10.3109/14767050903511560

Cited by 10 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The polarized secretion of sFlt-1 into the maternal compartment but not into the fetal side enables angiogenesis, which is essential for normal development to take place in the materno-fetal unit and is thought to protect the mother against excessive angiogenic stimulation. 53 In this study, maternal MDA levels showed an association with sFlt-1, which by itself has been shown to induce oxidative stress. A recent study in rats has shown that the chronic infusion of plasma sFlt-1 causes hypertension associated with increased oxidative stress and endothelial dysfunction, although the mechanism remains unknown.…”

Section: Discussionmentioning

confidence: 81%

“…As there is no increased demand for angiogenesis in the mother peripherally, maternal levels are low. 52,53 Slightly reduced VEGF levels in plasma may also be partly due to the complex with circulating sFlt-1 that is released from the placenta. The polarized secretion of sFlt-1 into the maternal compartment but not into the fetal side enables angiogenesis, which is essential for normal development to take place in the materno-fetal unit and is thought to protect the mother against excessive angiogenic stimulation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating angiogenic factors and their association with birth outcomes in preeclampsia

et al. 2010

View full text Add to dashboard Cite

This study was designed to test the hypothesis that altered angiogenic factors together with increased oxidative stress and reduced docosahexaenoic acid (DHA) levels may be associated with altered birth outcome parameters. To test this hypothesis, levels of plasma vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), the oxidative stress marker malondialdehyde (MDA) and fatty acids were estimated in women with preeclampsia and their cord samples and compared with those in normotensive women. The association of these parameters with birth outcome was also examined. Our results show that in preeclamptic women, maternal plasma VEGF and PlGF levels were lower, whereas sFlt-1 levels were higher (Po0.05 for all) than in normotensive women. In contrast, cord plasma VEGF levels were higher (Po0.05) in preeclamptic women, whereas there was no difference in sFlt-1 levels. Plasma DHA levels in both the mother and cord were lower (Po0.05) in the preeclamptic group compared with normotensive women. Maternal plasma sFlt-1 levels were positively (n¼23, r¼0.415, P¼0.039) associated with MDA concentrations in preeclamptic women. Maternal plasma sFlt-1 levels showed a strong negative association with baby weight (n¼37, r¼À0.547, P¼0.001), head circumference (n¼37, r¼À0.472, P¼0.005) and baby chest circumference (n¼37, r¼À0.375, P¼0.032) in the preeclamptic group. Cord plasma sFlt-1 concentrations were negatively associated with cord plasma DHA concentrations (n¼28, r¼À0.552, P¼0.004). This study suggests that dysregulation of angiogenic factors may be associated with maternal oxidative stress. Increased oxidative stress may reduce cord DHA levels and increase sFlt-1 levels, leading to poor birth outcomes in preeclampsia.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Circulating angiogenic factors and their association with birth outcomes in preeclampsia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Cord sFlt-1 levels were lower as compared to maternal levels at every time point during gestation. It has been reported that there is a polarized secretion of sFlt-1 into the maternal but not in the fetal compartment for angiogenesis [41].…”

Section: Discussionmentioning

confidence: 99%

Gestation Dependant Changes in Angiogenic Factors and Their Associations with Fetal Growth Measures in Normotensive Pregnancy

et al. 2013

View full text Add to dashboard Cite

BackgroundEarlier studies indicate that altered angiogenesis at birth is associated with poor birth outcome in women with preeclampsia. Now, we hypothesize that the progressive gestation dependant changes in markers of angiogenesis will be more useful to predict birth weight early even in a normotensive pregnancy. This study for the first time examines the association of gestation dependant changes in the levels of maternal angiogenic factors in addition to their levels in cord with birth weight.MethodNinety two pregnant women were followed at three different time points: 16–20 weeks, 26–30 weeks and at delivery during pregnancy. Plasma levels of angiogenic and anti angiogenic factors were determined by commercial enzyme-linked immunosorbent assay (ELISA) kits.ResultsMaternal plasma VEGF levels increased (p<0.01) till the second time point and decreased (p<0.05) up to delivery while plasma sFlt-1 levels increased (p<0.01) at delivery. PlGF levels peaked (p<0.01) at second time point and decreased (p<0.01) at delivery. Cord plasma VEGF levels were higher (p<0.01) and sFlt-1 levels were lower (p<0.01) as compared to maternal values at all time points. Maternal plasma VEGF levels at first time point and PlGF levels at delivery were positively (p<0.05 and p<0.01 respectively), while sFlt-1/PlGF ratio at delivery was negatively associated (p<0.05) with birth weight.ConclusionLevels of pro- and anti-angiogenic factors may be differentially regulated across gestation. Maternal VEGF levels at early gestation (16–20 weeks) may be predictive of birth weight in healthy term pregnancies.

show abstract

“…These 2 conditions combine in the hypertensive pregnancy, the most severe form of which is preeclampsia, which also implicates growth factor dysregulation. 6–26,32–34 Data on angiogenin and VEGF in preeclampsia are conflicting. For example, Reuvekamp et al 14 reported low VEGF but no difference in angiogenin in 30 women with preeclampsia (mean 524 ng/mL) compared with 30 NonPCs (mean 670 ng/mL), although P = .058 implies a type 1 (false negative due to small number) artifact.…”

Section: Discussionmentioning

confidence: 99%

Angiogenin and Hemoxygenase in Pregnancy

et al. 2011

View full text Add to dashboard Cite

The pathophysiology of hypertension and preeclampsia involves angiogenesis and endothelial damage/dysfunction, as shown by abnormal growth factors (vascular endothelial growth factor [VEGF], and its receptor sFlt-1) and von Willebrand factor (vWf) in the plasma. Angiogenin and hemoxygenase are abnormal in hypertension and angiogenesis but data on pregnancy are scant. We hypothesized altered angiogenin and hemoxygenase in 38 hypertensive pregnant women (HTPW) compared to 38 normotensive pregnant women (NTPW) and 50 nonpregnant controls (NonPCs). Plasma markers were measured by enzyme-linked immunosorbent assay (ELISA). Hypertensive pregnant women had lower VEGF than NonPCs (P< .01), vWf was raised in both pregnant groups (P < .01), but sFlt-1 was no different. Both angiogenin and hemoxygenase were lower in NTPW compared to NonPCs (both p<0.02). In both pregnancy groups, angiogenin correlated with vWf (r > .33, P < .05), but in NonPCs this was not significant (r = .13, P = .367). These changes may reflect differences in endothelial cell physiology and pathology in the hypertension in pregnancy.

show abstract

Concentrations of free vascular endothelial growth factor in the maternal and foetal circulations during pregnancy: A cross-sectional study

Cited by 10 publications

References 24 publications

Circulating angiogenic factors and their association with birth outcomes in preeclampsia

Circulating angiogenic factors and their association with birth outcomes in preeclampsia

Gestation Dependant Changes in Angiogenic Factors and Their Associations with Fetal Growth Measures in Normotensive Pregnancy

Angiogenin and Hemoxygenase in Pregnancy

Contact Info

Product

Resources

About